NEW YORK (CNNMoney.com) - The FDA announced improved labeling for two topical eczema drugs, Elidel Cream and Protopic Ointment, which have been linked to rare reports of cancer.

The labeling will be updated with a boxed warning about potential cancer risk.

'Me-too' drugs rake in sales Copycats like Lipitor can make billions, or fail like Vioxx and Bextra. (Full story) Pharma news • Frist stem cell support boosts biotechs • Banning drug ads could cost $10B • Vytorin outsells rival cholesterol drugs

"We are taking steps to ensure that healthcare providers and patients are aware of the possible long-term risks of these products so that they will be used appropriately," said Dr. Steven Galson, Director of the FDA's Center for Drug Evaluation and Research.

Eczema is a common skin disorder, affecting as much as 15 percent of the childhood population.

The drugs had been of concern since the FDA issued a Public Health Advisory in March 2005 advising physicians about a potential cancer risk. A definitive causal link between the eczema drugs and cancer has not been established, although rare reports of skin cancer and lymphoma.

________________________

3pm slump? Wondering how to get more energy? Read the full story here.

For all the latest headlines in News, click here.